Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics has closed its underwritten public offering of common stock, including full exercise of underwriters’ option, resulting in gross proceeds of approximately $345 million. The offering was conducted under an existing shelf registration with the SEC. The funds are aimed to support the advancement of Celldex's clinical-stage pipelin…